1044243-51-7

Basic information

• Product Name: C₃₀H₃₆N₂O₅
• Synonyms: C₃₀H₃₆N₂O₅
• CAS NO: 1044243-51-7
• Molecular Weight: 504.626
• Mol File: 1044243-51-7.mol

Chemical Properties

• CAS DataBase Reference: C₃₀H₃₆N₂O₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₀H₃₆N₂O₅(1044243-51-7)
• EPA Substance Registry System: C₃₀H₃₆N₂O₅(1044243-51-7)

Safety Data

• Hazardous Substances Data: 1044243-51-7(Hazardous Substances Data)

Upstream product

• 32422-96-1 1-(Triphenylmethyl)piperazine 
• 76-83-5 trityl chloride 
• 914361-72-1 N-tritylpiperazine succinate 
• 1044243-49-3 trityl piperazine phenyl carbamate 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 

Downstream Products

• 1044243-53-9 1,12-dioxo-1-(4-tritylpiperazin-1-yl)-2,5,8,11-tetraoxa-15-pentadecanoic acid 
• 1380600-06-5 butanedioic acid, 1-[(3aR,4S,7R,7aS)-1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl] 4-[2-[2-[2-[[[4-(triphenylmethyl)-1-piperazinyl]carbonyl]oxy]ethoxy]ethoxy]ethyl] ester 
• 1044243-54-0 C₄₃H₄₇N₃O₁₀ 

Relevant articles and documents

EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY

Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 50 skipping are described. In various aspects, antisense oligomers are described according to Formula (I): or a pharmaceutically acceptable salt thereo

Antisense-induced exon exclusion in type VII collagen

The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.

PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS

Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.

EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY

Antisense oligomers and antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.

EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY

Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.

EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY

Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.

EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY

Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.

PROCESSES FOR PREPARING OLIGOMERS

Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.

COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS

The present disclosure relates to compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders. Modified antisense oligomers are disclosed for the treatment of Duchenne muscular dystrophy and related disorders.

EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.